Research programme: rheumatoid arthritis stem cell therapies - Benitec Biopharma/Intrexon

Drug Profile

Research programme: rheumatoid arthritis stem cell therapies - Benitec Biopharma/Intrexon

Latest Information Update: 12 Mar 2014

Price : $50

At a glance

  • Originator Benitec Ltd; MediStem Laboratories
  • Developer Benitec Biopharma; Medistem
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 12 Mar 2014 No development reported - Preclinical for Rheumatoid arthritis in Australia (Parenteral)
  • 12 Mar 2014 No development reported - Preclinical for Rheumatoid arthritis in USA (Parenteral)
  • 07 Mar 2014 Medistem has been acquired by Intrexon Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top